Oral Cancer News – Page 187 – The Oral Cancer Foundation News Archive

Asparagus as antimicrobial agent in oral cancer infections

Source: www.insidecosmeceuticals.com Author: staff According to Indian researchers, treated oral cancer patients are neutropenic and prone to secondary infection of microbes, and medicinal plants such as asparagus may serve as effective antimicrobial agents to check the secondary infections in treated oral cancer patients (Ann Clin Microbiol Antimicrob. 2011;10:21). Suppression of immune system in treated cancer patients may lead to secondary infections that obviate the need of antibiotics. In the present study, an attempt was made to understand the occurrence of secondary infections in immunosuppressed patients along with herbal control of these infections with the following objectives to: (a) isolate the microbial species from the treated oral cancer patients along with the estimation of absolute neutrophile counts of patients (b) assess the in vitro antimicrobial activity medicinal plants against the above clinical isolates. Blood and oral swab cultures were taken from 40 oral cancer patients undergoing treatment in the radiotherapy unit of Regional Cancer Institute, Pt. B.D.S. Health University,Rohtak, Haryana. Clinical isolates were identified by following general microbiological, staining and biochemical methods. The absolute neutrophile counts were done by following the standard methods. The medicinal plants selected for antimicrobial activity analysis were Asphodelus tenuifolius Cav., Asparagus racemosus Willd., Balanites aegyptiaca L., Cestrum diurnum L., Cordia dichotoma G. Forst, Eclipta alba L., Murraya koenigii (L.) Spreng. , Pedalium murex L., Ricinus communis L. and Trigonella foenum graecum L. Prevalent bacterial pathogens isolated were Staphylococcus aureus (23.2 percent), Escherichia coli (15.62 percent), Staphylococcus epidermidis (12.5 percent), Pseudomonas aeruginosa (9.37 percent), Klebsiella pneumonia (7.81 [...]

Oral Cancer Foundation News Team - A2011-08-11T12:53:42-07:00August, 2011|Oral Cancer News|

Neoprobe enrolling patients in head and neck cancer trial

Source: www.medcitynews.com Author: Brandon Glenn Cancer diagnostics company Neoprobe is continuing to enroll patients in a phase 3 head and neck cancer clinical trial of its radiopharmaceutical Lymphoseek. The trial is aimed at expanding Lymphoseek’s label to cover procedures known as sentinel lymph node biopsies, CEO Mark Pykett said in a conference call with investors. The sentinel lymph node is the first lymph node to which cancer is likely to spread from the primary tumor, according to the National Cancer Institute. Neoprobe on Wednesday announced that it had filed a New Drug Application for Lymphoseek, but that filing sought labeling for a different clinical indication: intraoperative lymphatic mapping, which is a surgical oncology procedure in which lymph nodes draining the area around a tumor are identified to determine if cancer has spread to the lymph nodes. That procedure is typically used for patients with breast cancer or melanoma. Neoprobe’s head and neck cancer clinical trial is expected to enroll 200 patients. The study’s estimated completion date is March 2013, according to information the company has filed with the National Institutes of Health. In addition to expanding Lymphoseek’s label, Neoprobe is looking to strike deals with potential European and Asian distribution, and sales and marketing partners for the drug. Cardinal Health is handling U.S. distribution and sales and marketing of Lymphoseek. Lymphoseek has not been approved for sales anywhere in the world, but could obtain approval in the U.S. by the middle of next year. Here’s how Pykett laid out his [...]

Oral Cancer Foundation News Team - A2011-08-11T12:49:35-07:00August, 2011|Oral Cancer News|

Stroke and TIA risk doubled by radiotherapy, study finds

Source: www.imt.ie Author: Mary Anne Kenny The risk of transient ischaemic attack (TIA) or ischaemic stroke is at least doubled by head and neck radiotherapy, a problem increasing in urgency as patients survive their malignancies longer, an Australian review of the literature has concluded. Besides case reports, the reviewers found 77 studies of stroke, TIA or rates of carotid stenosis in patients who had received radiation therapy for primary or secondary cancers of the head or neck region. The 17 epidemiological studies revealed that the procedures appear to “at least double” the relative risk of TIA or stroke, with the exception of adjuvant neck radiotherapy for breast cancer where no association was found. Radiotherapy for breast cancer resulted in only the carotid artery only being minimally exposed to radiation, the authors reported in Stroke. The evidence for radiation vasculopathy (defined as chronic occlusive cerbrovascular disease affecting medium- and large-diameter arteries) was strongest where the exposure occurred in childhood, but the exact magnitude of the increase was unclear due to heterogeneity in the studies. Considering the 17 imaging studies, the reviewers found they repeatedly showed “an increased prevalence of haemodynamically significant carotid stenosis” when there was a history of head and neck radiotherapy. The most significant radiologic evidence implicating radiotherapy in TIA and stroke was the spatial distribution of the vascular disease itself, they said. “It signposts the [radiotherapy] field.” Two theories of the pathogenesis of radiation vasculopathy were presented in the literature, they said. One was that it was an [...]

Oral Cancer Foundation News Team - A2011-08-11T07:21:03-07:00August, 2011|Oral Cancer News|

Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma

Source: 7thspace.com Author: Emina Besic Gyenge et al. Head and neck squamous cell carcinoma (HNSCC) is currently the eighth leading cause of cancer death worldwide. The often severe side effects, functional impairments and unfavorable cosmetic outcome of conventional therapies for HNSCC have prompted the quest for novel treatment strategies, including the evaluation of nanotechnology to improve drug delivery and cancer imaging. Although silica nanoparticles hold great promise for biomedical applications, they have not yet been investigated in the context of HNSCC. In the present in-vitro study we thus analyzed the cytotoxicity, uptake and intracellular fate of 200-300 nm core-shell silica nanoparticles encapsulating fluorescent dye tris(bipyridine)ruthenium(II) dichloride with hydroxyl-, aminopropyl- or PEGylated surface modifications (Ru@SiO2-OH, Ru@SiO2-NH2, Ru@SiO2-PEG) in the human HNSCC cell line UMB-SCC 745. Results: We found that at concentrations of 0.125 mg/ml, none of the nanoparticles used had a statistically significant effect on proliferation rates of UMB-SCC 745. Confocal and transmission electron microscopy showed an intracellular appearance of Ru@SiO2-OH and Ru@SiO2-NH2 within 30 min. They were internalized both as single nanoparticles (presumably via clathin-coated pits) or in clusters and always localized to cytoplasmic membrane-bounded vesicles. Immunocytochemical co-localization studies indicated that only a fraction of these nanoparticles were transferred to early endosomes, while the majority accumulated in large organelles. Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles had never been observed to traffic to the lysosomal compartment and were rather propagated at cell division. Intracellular persistence of Ru@SiO2-OH and Ru@SiO2-NH2 was thus traceable over 5 cell passages, but did not result in apparent changes [...]

Oral Cancer Foundation News Team - A2011-08-11T12:56:09-07:00August, 2011|Oral Cancer News|

Oral Cancer Prevention international lawsuit against Johnson & Johnson claims actions expected to cause over 7,300 oral cancers

Source: www.marketwatch.com Author: press release A lawsuit filed by Oral Cancer Prevention International (OCPI) against Johnson & Johnson in Federal Court in Trenton New Jersey claims that J&J's actions to protect the reputation of its Listerine mouthwash, which has been linked to oral cancer, can be expected to result in over 7,300 cases of otherwise preventable oral cancer across the US and over 1,120 such cancers in New York State alone. Some of the key markets impacted include: California, Colorado, Florida, Illinois, Michigan, New Jersey, Ohio, Pennsylvania, Tennessee, Texas, and Washington. "Oral cancer kills as many Americans as melanoma and twice as many as cervical cancer," says Mark Rutenberg, CEO of OCPI. "It is also rising sharply among women, young people and non-smokers. Because there has previously not been an easy way to test routine oral spots for precancerous cells, the disease is generally not detected until it is an already invasive cancer with a high mortality rate that has changed little in the last 50 years." The lawsuit, which seeks compensatory and punitive damages, claims that J&J blocked an agreement between OCPI and a then J&J subsidiary to sell its test for oral precancer. The lawsuit claims that J&J was concerned that such sales could draw attention in the $1B US Listerine market to recent studies suggesting that the mouthwash may be linked to oral cancer. J&J was particularly concerned about a 2008 study in the Australian Dental Journal -- which concluded that mouthwashes with high alcohol content could [...]

Oral Cancer Foundation News Team - A2011-08-11T07:08:35-07:00August, 2011|Oral Cancer News|

New Study for Head and Neck Melanomas

Source: MDNews.com ANN ARBOR, MI — A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center. Sentinel lymph node biopsy involves injecting a special dye to identify the first node where cancer would likely spread. If that node is clean, patients can avoid further debilitating surgery to remove multiple lymph nodes. If that node shows cancer, patients know they need the more extensive surgery or further treatment with radiation, chemotherapy or a clinical trial. Patients with larger melanomas are routinely offered this procedure. But many surgeons believed that the complex anatomy combined with the critical nerves and blood vessels in the head and neck area made sentinel lymph node biopsy unsafe and inaccurate for melanomas in that region. In the current study, which appears online in Cancer, researchers looked at 353 head and neck melanoma patients who had received sentinel lymph node biopsy at U-M over a 10-year period. After reviewing patients’ records, the researchers found that the sentinel lymph node could be identified in all but one patient, and no patients sustained permanent nerve injuries during the procedure. About 20 percent of the patients had at least one sentinel node positive for cancer and were referred for a complete dissection to remove additional lymph nodes. Among the remaining 283 patients with negative sentinel nodes, 12 patients recurred in the region where the [...]

Oral Cancer Foundation News Team - A2011-08-09T10:30:24-07:00August, 2011|Oral Cancer News|

Aerosmith’s Bassist is Treated for Tongue Cancer with Laser Surgery

Source: KSAT.com Aerosmith will be performing in Mexico and South America this fall and one of the band members will be along for the tour thanks to a radical medical procedure. In one Aerosmith song, bassist Tom Hamilton sends a message to his throat and tongue cancer with the lyrics "you've got no business with me." Five years ago, Hamilton underwent chemotherapy and radiation for tongue-base cancer, but it came back and extended into his voice box. That is when he turned to Dr. Steven Zeitels. "This is not your classic way, or even traditional way, to try and remove a cancer from the tongue base," Zeitels said. Radical surgery was now Hamilton's only option. But that could leave his voice and breathing passage permanently damaged. "I was just terrified," Hamilton said. "I really though, 'Oh, I am looking at not being able to talk.'" Zeitels has treated vocal cord cancer with the green-light KTP laser, so Hamilton agreed to be the first person treated that way for tongue base cancer. The laser emits a green light, which is concentrated in the extra blood running through the cancer. "Where there is a lot of cancer, there will be a lot of blood," Zeitels said. "Where there is a lot of blood, there will be a lot of combustion so that you are actually watching the tissues burn completely different" But not everyone is a candidate for this surgery. "The second I had a tiny bit of consciousness, the first thing I did was make [...]

Oral Cancer Foundation News Team - A2011-08-09T10:30:12-07:00August, 2011|Oral Cancer News|

Reirradiation Effective in Post-Radiation Sarcoma

Source: MedScape Today News Reirradiation plus hyperthermia is an effective treatment for radiation-associated sarcoma (RAS) and could even cure some of these rare tumors, a small new study suggests. "The reirradiation plus hyperthermia as we used it appears to be quite successful with a very high response rate and reasonable local control rate," Dr. Geertjan van Tienhoven of the Academic Medical Center in Amsterdam, one of the study's authors, told Reuters Health. RAS develops in areas previously reirradiated with 25 to 80 Gray, usually with a latency period of three years or more, and with a different histology from the original tumor, according to a June 28th online paper in Cancer. Dr. van Tienhoven predicts that "radiation-associated sarcomas are going to be more frequent in the future, because of an increasing prevalence of breast cancer survivors who are at risk, be it a low risk, for RAS." These tumors are usually resected with radical surgery and sometimes adjuvant chemotherapy. To date, according the paper, there haven't been any randomized trials or other prospective studies of reirradiation for RAS. "Many papers and textbooks state that radiation shouldn't be done in these tumors because they are caused by radiation. Indeed it sounds counterintuitive to irradiate again," Dr. van Tienhoven said in an interview. But using hyperthermia with reirradiation allows for a lower radiation dose, he and his coauthors explain. The Academic Medical Center and the Institute Verbeeten have "extensive experience" with this approach, for example in breast cancer recurrence in previously irradiated [...]

Oral Cancer Foundation News Team - A2011-08-09T10:29:53-07:00August, 2011|Oral Cancer News|

Laser Surgery On Tongue Cancer Successful for Aerosmith Musician

Source: KSAT Author: Brian Mylar Aerosmith Musician Shows Progress Fighting Cancer SAN ANTONIO -- Aerosmith will be performing in Mexico and South America this fall and one of the band members will be along for the tour thanks to a radical medical procedure. In one Aerosmith song, bassist Tom Hamilton sends a message to his throat and tongue cancer with the lyrics "you've got no business with me." Five years ago, Hamilton underwent chemotherapy and radiation for tongue-base cancer, but it came back and extended into his voice box. That is when he turned to Dr. Steven Zeitels. "This is not your classic way, or even traditional way, to try and remove a cancer from the tongue base," Zeitels said. Radical surgery was now Hamilton's only option. But that could leave his voice and breathing passage permanently damaged. "I was just terrified," Hamilton said. "I really though, 'Oh, I am looking at not being able to talk.'" Zeitels has treated vocal cord cancer with the green-light KTP laser, so Hamilton agreed to be the first person treated that way for tongue base cancer. The laser emits a green light, which is concentrated in the extra blood running through the cancer. "Where there is a lot of cancer, there will be a lot of blood," Zeitels said. "Where there is a lot of blood, there will be a lot of combustion so that you are actually watching the tissues burn completely different" But not everyone is a candidate for this surgery. [...]

Charlotte Parker2011-08-08T16:41:44-07:00August, 2011|Oral Cancer News|

How Norwich woman put the “fun” in fundraising

Source: Norwich evening news Author: Rowan Mantell She’s enlisted elephants and garden gnomes to her cause, met royalty, staged an impromptu strip show and helped make millions for charity. Theresa Cossey, who has just stepped down as a trustee of the Big C charity, talks about putting the fun into fundraising. She spoke to ROWAN MANTELL. All her life Theresa Cossey has fizzed with money-making ideas. Elephants and garden gnomes were early stars of her fund-raising fervour, and over the past 30 years she has helped raise millions for Norfolk charity Big C – with everything from huge society events to tiny table-top tombolas. She has encouraged people who have run marathons, rafted across the Channel, embarked on sponsored tandem rides in pantomime costume, raced hospital trollies and auctioned anything from bedspreads to baby donkeys. Theresa is, quite simply, a phenomenal fundraiser. Since 1980 she has raised big, big money for Big C, and despite the decades of hard graft, she still believes fund-raising is all about having fun. “Fundraising should be without the final ‘d’; it should be fun, and if it stops being fun you should stop doing it,” she said. That fun has funded hospital wards and equipment, paid for practical and emotional support for cancer patients and their families, and set up teams of scientists researching treatments and cures. This summer Theresa is handing over some of her Big C responsibilities, but not because she has lost her passion for the charity. “When you get past 70 [...]

Charlotte Parker2011-08-08T12:11:43-07:00August, 2011|Oral Cancer News|